A new nitric oxide scavenger, imidazolineoxyl N-oxide derivative, and its effects in pathophysiology and microbiology.

[1]  H. Maeda,et al.  Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. , 1994, Biochemical and biophysical research communications.

[2]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor , 1994, Japanese journal of cancer research : Gann.

[3]  H. Maeda,et al.  Pronounced enhancement of .NO-dependent antimicrobial action by an .NO-oxidizing agent, imidazolineoxyl N-oxide , 1993, Infection and immunity.

[4]  F. Walker,et al.  Reversible binding of nitric oxide by a salivary heme protein from a bloodsucking insect. , 1993, Science.

[5]  H. Maeda,et al.  Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. , 1993, Biochemistry.

[6]  S. Gross,et al.  Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. , 1992, The Journal of biological chemistry.

[7]  D. Harrison,et al.  Release of Multiple Endothelium‐Derived Relaxing Factors from Porcine Coronary Arteries , 1992, Journal of cardiovascular pharmacology.

[8]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[9]  J. Stamler,et al.  Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  O. Griffith,et al.  Overproduction of nitric oxide in cytokine-mediated and septic shock. , 1992, Journal of the National Cancer Institute.

[11]  M. Yacoub,et al.  Comparison of cyclic GMP in human internal mammary artery and saphenous vein: implications for coronary artery bypass graft patency. , 1992, Cardiovascular research.

[12]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[13]  Tetsurou Yamamoto,et al.  Kinin‐generating Cascade in Advanced Cancer Patients and in vitro Study , 1991, Japanese journal of cancer research : Gann.

[14]  C. Nathan,et al.  Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  S. Skinner,et al.  Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.

[16]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[17]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[18]  Tetsurou Yamamoto,et al.  Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue , 1988, Japanese journal of cancer research : Gann.

[19]  H. Maeda,et al.  Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. , 1988, The Journal of biological chemistry.

[20]  J. Schrader,et al.  Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. , 1988, Biochemical and biophysical research communications.

[21]  R. Puri,et al.  Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. , 1988, Journal of the National Cancer Institute.

[22]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[23]  Tohru Takahashi,et al.  Medial regression and its functional significance in tumor‐supplying host arteries. A morphometric study of hepatic arteries in human livers with hepatocellular carcinoma , 1987, Cancer.

[24]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[25]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[26]  H. Maeda,et al.  Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. , 1984, Cancer research.

[27]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[28]  S. Gatley,et al.  The effects of diphenyleneiodonium on mitochondrial reactions. Relation of binding of diphenylene[125I]iodonium to mitochondria to the extent of inhibition of oxygen uptake. , 1976, The Biochemical journal.

[29]  N. Sakai,et al.  Tetrahydrobiopterin is required for cytokine-induced nitric oxide production in a murine macrophage cell line (RAW 264). , 1993, Molecular pharmacology.

[30]  J. Drapier.  L-arginine-derived nitric oxide and the cell-mediated immune response. 39th Forum in Immunology. , 1991, Research in immunology.

[31]  S. Snyder,et al.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.